An overview of raltitrexed in advanced colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2018.01.013

Abstract

Abstract:

Fluorouracil-based chemotherapy is the standard regimen for patients with colorectal cancer, and it makes admirable survival benefit. However, it would represent a formidable challenge of no other useful drug when they were resistant. Recently, the contradiction was alleviated to some extent by the application of raltitrexed. Here, we provide a brief review of the current researches about mechanism of raltitrexed and the clinical results of raltitrexed-based chemotherapy in advanced colorectal cancer.

Key words: Colorectal neoplasms, Flurouracil, Raltitrexed, Advanced stage, Chemotherapy

Zhenhai Wu, Xiujuan Qu. An overview of raltitrexed in advanced colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2018, 07(01): 62-66.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2018.01.013

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2018/V07/I01/62

References 38

[1]	Hermann B, Matthias K, Christian Peter P. Colorectal cancer [J]. Lancet, 2014, 383(9927): 1490-1502.
[2]	Barni S, Ghidini A, Coinu A, et al. A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer [J]. Anti-cancer drugs, 2014, 25(10): 1122-1128.
[3]	Antonio A, Elena DG, Lucrezia S, et al. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed [J]. Expert Opin Drug Saf，2014, 13(1): 113-129.
[4]	王佳蕾，李进，秦叔逵, 等. 雷替曲塞或氟尿嘧啶/亚叶酸钙联合奥沙利铂治疗局部晚期或复发转移性结直肠癌的随机对照多中心Ⅲ期临床试验 [J]. 临床肿瘤学杂志, 2012, 17(1): 6-11.
[5]	Kelly C, Bhuva N, Harrison M, et al. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history [J]. European Journal of Cancer, 2013, 49(10): 2303-2310.
[6]	Ransom D, Wilson K, Fournier M, et al. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines [J]. Annals of Oncology, 2014, 25(1): 117-121.
[7]	Liu Y, Wu W, Hong W, et al. Raltitrexed-based chemotherapy for advanced colorectal cancer [J]. Gastroentérologie Clinique Et Biologique, 2013, 38(2): 219-225.
[8]	陈建林，宋卫峰，陈栋晖. 雷替曲塞治疗晚期结直肠癌临床疗效的Meta分析 [J]. 中国新药与临床杂志, 2010, 29(11): 853-857.
[9]	Xue S, Chen Y X, Qin S K, et al. Raltitrexed induces mitochondrialmediated apoptosis in SGC7901 human gastric cancer cells [J]. Molecular medicine reports, 2014, 10(4): 1927-1934.
[10]	Zhao H, Zhang Y, Sun J, et al. Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest [J]. Oncology Research Featuring Preclinical & Clinical Cancer Therapeutics, 2016, 23(5): 237-248.
[11]	程燕，周恒根，刘兰芳, 等. 雷替曲塞联合奥沙利铂治疗晚期胃癌的疗效观察 [J]. 中国现代药物应用, 2015, 9(5): 16-18.
[12]	Zhao C, Fan L, Qi F, et al. Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma [J]. Anti-cancer drugs, 2016, 27(7): 689-694.
[13]	Li XY, Liu L, Xie XM, et al. The role of raltitrexed/cisplatin with concurrent radiation therapy in treating advanced cervical cancer [J]. European Review for Medical & Pharmacological Sciences, 2014, 18(22): 3491-3496.
[14]	张淼慈，哈敏文. 培美曲塞或雷替曲塞联合顺铂一线治疗恶性胸膜间皮瘤的疗效与安全性观察 [J]. 解放军医学院学报, 2014, 35(10): 1004-1007.
[15]	覃金莲，陆永奎，刘莎, 等. 雷替曲塞对比5-氟尿嘧啶一线治疗晚期结直肠癌疗效和不良反应的Meta分析 [J]. 中国现代医学杂志, 2013, 23(14): 84-90.
[16]	Scheithauer W, Kornek G V, Raderer M, et al. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer [J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2002, 20(1): 165-172.
[17]	Nishisho I, Kikkawa N, Ebata T, et al. A late phase II study of raltitrexed (ZD 1694) in chemotherapy-naive patients with advanced colorectal cancer [J]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, 27(1): 81-91.
[18]	Cunningham D, Zalcberg J R, Rath U, et al. 'Tomudex’ (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The ′Tomudex′ Colorectal Cancer Study Group [J]. European Journal of Cancer, 1995, 31A(12): 1945-1954.
[19]	Cocconi G, Cunningham D, Van CE, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group [J]. Journal of Clinical Oncology, 1998, 16(9): 2943-2952.
[20]	Sato A, Kurihara M, Horikoshi N, et al. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group [J]. Anti-cancer drugs, 1999, 10(8): 741-748.
[21]	余嘉文. 雷替曲塞单药二线治疗晚期大肠癌疗效观察 [J]. 中国现代药物应用, 2012, 6(4): 18-19.
[22]	纪丕军，白威，杨迁妮. 雷替曲塞单药方案三线治疗晚期结直肠癌的疗效观察 [J]. 山西医药杂志, 2016, 45(13): 1567-1569.
[23]	封革，胡萍，高金锋, 等. 雷替曲塞在晚期结直肠癌三线治疗的临床观察 [J]. 医学信息, 2016, 29(18): 69-70.
[24]	成科，刘继彦. 雷替曲塞在晚期结直肠癌治疗中的应用 [J]. 华西医学, 2010，25(11): 1996-2000.
[25]	Chiara S, Nobile MT, Tomasello L, et al. Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer [J]. Anticancer research, 2005, 25(2B): 1391-1396.
[26]	Aparicio J, Vicent J M, Maestu I, et al. First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study [J]. Oncology, 2005, 68(1): 58-63.
[27]	Feliu J, Salud A, Escudero P, et al. Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study [J]. Br J Cancer, 2004, 90(8): 1502-1507.
[28]	Aparicio J, Vicent J M, Maestu I, et al. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer [J]. Annals of Oncology, 2003, 14(7): 1121-1125.
[29]	Vandendriessche B, Geurs F, Hilderson I. Raltitrexed + irinotecan as second-line chemotherapy in elderly patients with advanced colorectal cancer [J]. Modern Chemotherapy, 2012, 1(2): 5-10.
[30]	刘连科，邵明雯，孙婧, 等. 雷替曲塞联合伊立替康三线治疗晚期结直肠癌疗效及安全性分析 [J]. 实用临床医药杂志, 2013, 17(24): 111-112.
[31]	谢达成，李宁，王静珏, 等. 雷替曲塞联合伊立替康2周方案对比FOLFIRI方案二线治疗晚期结直肠癌的疗效观察 [J]. 临床肿瘤学杂志, 2013, 18(2): 140-143.
[32]	Gravalos C, Salut A, García-Girón C, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer [J]. Clinical and Translational Oncology, 2012, 14(8): 606-612.
[33]	Feliu J, Castanon C, Salud A, et al. Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer [J]. British journal of cancer, 2005, 93(11): 1230-1235.
[34]	董保国，谢桂生，李霖, 等. 雷替曲塞联合奥沙利铂治疗术后复发晚期大肠癌的疗效观察 [J]. 中国医学创新, 2014, 11(2): 15-16.
[35]	宋文灿，潘明，徐金发, 等. 雷替曲塞联合奥沙利铂在结直肠癌一线治疗失败后的临床应用 [J]. 安徽医学, 2014, 39(5): 641-644.
[36]	黄建国，张建华，陆建伟. 雷替曲塞联合奥沙利铂方案二线治疗晚期结直肠癌的疗效观察 [J]. 肿瘤基础与临床, 2016, 29(1): 36-39.
[37]	Cheng K, Chen Y, Li L H, et al. Raltitrexed combined with bevacizumab in heavily pretreated metastatic colorectal cancer [J]. Journal of Cancer Research & Therapeutics, 2013, 9(4): 727-729.
[38]	杨建伟，林锦源，高炜, 等. 雷替曲塞/贝伐珠单抗联合伊立替康或奥沙利铂方案治疗晚期结直肠癌的临床观察 [J]. 临床肿瘤学杂志, 2013, 18(1): 70-73.

Please choose a citation manager

Content to export